Figure 1: Mortality observed in patients using monotherapy of cardiac and NPMs. The highest mortality for patients taking NPMs was seen with antiseizure (10.0%, 2/20) and antipsychotic use (8.6%, 3/35). These mortalities were not significantly different than patients that were not taking NPMs (7.2%, 27/376). The highest mortality with cardiac monotherapies was seen in patients taking β-blockers (4.8%, 4/83) and ACEI/ARBs (4.9%, 4/82). These mortalities were not significantly different from patients that were not taking cardiac medications (4.2%, 17/357)